Trials / Recruiting
RecruitingNCT06307795
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Avistone Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANS014004 | Varying doses of ANS014004 |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2027-04-01
- Completion
- 2027-10-01
- First posted
- 2024-03-13
- Last updated
- 2026-04-17
Locations
15 sites across 3 countries: United States, Canada, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06307795. Inclusion in this directory is not an endorsement.